Immunome (IMNM)

Executive Summary

Immunome is a clinical-stage oncology company specializing in antibody-drug conjugates (ADCs) and targeted cancer therapies. Its lead program, AL102 (varegacestat), is a gamma secretase inhibitor in a Phase 2/3 trial for desmoid tumors, a rare soft tissue condition with high unmet need. The trial is active and expected to complete in October 2026, with potential top-line data anticipated in mid-2026. Immunome is also advancing IM-1021, a ROR1-targeted ADC in Phase 1 for solid and hematologic malignancies, with initial results expected in 2026. Additionally, the company has a FAP-targeted radioligand therapy (RLT) that has received IND clearance, positioning it for Phase 1 initiation. With a seasoned management team and a pipeline focused on first-in-class therapies, Immunome represents a compelling investment opportunity in oncology, particularly if AL102 demonstrates a favorable efficacy and safety profile. The company's valuation of ~$2.6B reflects the potential of its late-stage asset, though risk remains pending trial outcomes.

Upcoming Catalysts (preview)

• Q3 2026AL102 Phase 2/3 top-line data readout for desmoid tumors65% success
• Q2 2026IM-1021 Phase 1 interim efficacy and safety data50% success
• Q4 2026Phase 1 trial initiation of FAP-targeted radioligand therapy80% success